• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Sprint Bioscience

3.43 SEK

+3.63 %

Less than 1K followers

SPRINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.63 %
+6.52 %
+78.65 %
+133.33 %
+115.72 %
+716.67 %
+491.16 %
-14.46 %
-70.78 %

Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.

Read more
Market cap
361.92M SEK
Turnover
2.42M SEK
Revenue
167.17M
EBIT %
58.2 %
P/E
3.46
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28/8
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

11/2
2027

Annual report '26

Third party researchyesterday

Sprint Bioscience: Innovation och affär - Analysguiden

Sprint Bioscience intar en speciell roll inom svensk läkemedelsutveckling. Bolaget har en relativt omfattande preklinisk portfölj av olika program inom innovativ cancerforskning och vi räknar med att dessa program ska tillåta bolaget att fortsätta gö...

Sprint Bioscience
Press releaseyesterday

Analysguiden: INITIERINGSANALYS Sprint Bioscience: Innovation och affär

Sprint Bioscience
Press releaseyesterday

Sprint Bioscience (publ) meddelar att Aktiespararna initierar uppdragsanalys av bolaget

Sprint Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press releaseyesterday

Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company

Sprint Bioscience
Press release5/19/2026, 9:14 AM

Redeye: Sprint Bioscience (Q1 Review): Momentum in the business

Sprint Bioscience
Regulatory press release5/13/2026, 1:28 PM

Kommuniké från årsstämma i Sprint Bioscience AB (publ)

Sprint Bioscience
Regulatory press release5/13/2026, 5:30 AM

Sprint Bioscience delårsrapport för januari – mars 2026

Sprint Bioscience
Press release4/16/2026, 6:00 AM

Sprint Bioscience slutför strategisk STK25-utvärdering; fortsatt fokus på den primära indikationen

Sprint Bioscience
Press release4/16/2026, 6:00 AM

Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication

Sprint Bioscience
Regulatory press release4/15/2026, 10:15 AM

Sprint Bioscience årsredovisning

Sprint Bioscience
Regulatory press release4/9/2026, 2:10 PM

Kallelse till årsstämma i Sprint Bioscience AB (publ)

Sprint Bioscience
Regulatory press release4/1/2026, 8:55 AM

Sprint Bioscience utser Jenni Björnulfson till CFO

Sprint Bioscience
Regulatory press release4/1/2026, 8:55 AM

Sprint Bioscience appoints Jenni Björnulfson as CFO

Sprint Bioscience
Press release4/1/2026, 6:00 AM

Positiva resultat breddar NNMT-programmet till kronisk njursvikt

Sprint Bioscience
Press release4/1/2026, 6:00 AM

Positive results expand the NNMT program into Chronic Kidney Disease

Sprint Bioscience
Press release3/27/2026, 9:00 AM

Sprint Bioscience publishes new research findings that strengthen the potential of DCPS inhibitors in AML

Sprint Bioscience
Press release3/27/2026, 9:00 AM

Sprint Bioscience publicerar nya forskningsresultat som stärker potentialen för DCPS-hämmare inom AML

Sprint Bioscience
Press release3/20/2026, 11:15 AM

Sprint Biosciences kommande aktiviteter

Sprint Bioscience
Press release3/18/2026, 6:45 AM

Sprint Biocience presenterar ny preklinisk data om DCPS på AACR Annual Meeting 2026

Sprint Bioscience
Press release3/18/2026, 6:45 AM

Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026

Sprint Bioscience